Megan Appleby
Lawrenceville, GANPI 1336636497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 321 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,006, more than ten times the $183 reported in 2021.
Across 321 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$657
- Otsuka America Pharmaceutical, Inc.$477
- Novo Nordisk$350
- Pfizer$338
- Lilly USA, LLC$307
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,806100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,392 |
| Amgen | 36 | $657 |
| Otsuka America Pharmaceutical, Inc. | 24 | $477 |
| Novo Nordisk | 25 | $350 |
| Pfizer | 15 | $338 |
| Lilly USA, LLC | 17 | $307 |
| GSK | 8 | $265 |
| AstraZeneca | 12 | $262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $256 |
| Vanda Pharmaceuticals Inc. | 13 | $229 |
| Boehringer Ingelheim | 3 | $169 |
| Paratek Pharmaceuticals, Inc. | 7 | $138 |
| Lundbeck LLC | 5 | $132 |
| Novartis | 5 | $112 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| Grifols USA, LLC | 4 | $84 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Jazz Pharmaceuticals Inc. | 3 | $78 |
| Astellas Pharma US Inc | 3 | $75 |
| Axsome Therapeutics, Inc. | 1 | $72 |
| Bayer | 3 | $50 |
| Inspire Medical Systems, Inc. | 2 | $50 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Boston Scientific | 1 | $17 |
| Atland Pharmaceuticals, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$122
- TRELEGY ELLIPTA$121
- JARDIANCE$118
- VRAYLAR$102
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $90,785 |
| MounjaroTirzepatide | 62 | $68,037 |
| TrulicityDulaglutide | 52 | $60,073 |
| Metformin Er GastricMetformin Hcl | 11 | $43,386 |
| FarxigaDapagliflozin Propanediol | 42 | $39,787 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $38,808 |
| JardianceEmpagliflozin | 34 | $37,519 |
| EliquisApixaban | 33 | $27,776 |
| JanuviaSitagliptin Phosphate | 16 | $17,052 |
| Diclofenac Sodium | 30 | $12,857 |
| VascepaIcosapent Ethyl | 14 | $6,863 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $5,871 |
| BelsomraSuvorexant | 12 | $5,327 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,612 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $307 | $128,110114 claims |
| Novo NordiskOzempic | $350 | $90,78586 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy | $265 | $48,01974 claims |
| AstraZenecaFarxiga, Symbicort | $262 | $43,94356 claims |
| Boehringer IngelheimJardiance | $169 | $37,51934 claims |
| PfizerEliquis | $338 | $27,77633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.